HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alanod D Al Qahtani Selected Research

ZD 2767

1/2021Production of Long-Acting CNGRC-CPG2 Fusion Proteins: New Derivatives to Overcome Drug Immunogenicity of Ligand-Directed Enzyme Prodrug Therapy for Targeted Cancer Treatment.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Alanod D Al Qahtani Research Topics

Disease

1Neoplasms (Cancer)
01/2021

Drug/Important Bio-Agent (IBA)

1ZD 2767IBA
01/2021
1Pharmaceutical PreparationsIBA
01/2021
1EnzymesIBA
01/2021
1LigandsIBA
01/2021
1ProdrugsIBA
01/2021
1Proteins (Proteins, Gene)FDA Link
01/2021
1CD13 Antigens (Alanine Aminopeptidase)IBA
01/2021

Therapy/Procedure

1Therapeutics
01/2021